A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Atacicept (Primary)
- Indications IgA nephropathy; Proteinuria
- Focus Adverse reactions; Therapeutic Use
- Sponsors EMD Serono Research & Development Institute; Merck Serono
- 01 Aug 2018 Planned End Date changed from 17 Aug 2022 to 4 Jun 2021.
- 01 Aug 2018 Planned primary completion date changed from 4 May 2021 to 4 Jun 2021.
- 31 May 2018 Planned primary completion date changed from 30 Jul 2020 to 4 May 2021.